A/Prof Andre Choo obtained his PhD from the University of Technology Sydney focusing on the molecular engineering of antibody fragments and immunotoxins. He was also involved in the characterization of a mAb that induced apoptosis of kappa-myelomas. This is currently pursued by HaemaLogiX in Phase II clinical trials. Moving back to Singapore, he continued to pursue his interest in antibody discovery and was responsible for the discovery of mAb 84, a first in class antibody that selectively kills undifferentiated pluripotent stem cells making cell therapy safer. Their lead oncology asset, EBC-129, the first Made-in-Singapore Antibody-Drug Conjugate was approved in Jan 2023 by the US FDA and Singapore’s HSA for first-in-man clinical trials progresses to Phase 1B dose expansion. He currently holds the position of Deputy Executive Director and Group Leader at the Bioprocessing Technology Institute (BTI), and Adjunct Professor at the Department of Biomedical Engineering, National University of Singapore.